Trial · NCT00592176
The Effect of Bevacizumab (Avastin) on Pterygium
NCT00592176, Phase 2, Completed, University of Alabama at Birmingham; results first posted 2012-06-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effect of Bevacizumab (Avastin) on Pterygium. Trials, record NCT00592176. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00592176
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effect of Bevacizumab (Avastin) on Pterygium
- NCT number
- NCT00592176
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- University of Alabama at Birmingham
- Conditions
- Pterygium
- Interventions
- local injection of bevacizumab
- First posted
- 2008-01-11
- Last updated
- 2014-06-04
- Results first posted
- 2012-06-25
- Limitations and caveats
- Initially we aimed for 10 to 15 subjects but only enrolled 5 subjects.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Area the Pterygium Enlarged or Regressed as Measured From the Limbus Before and After Subconjunctival Bevacizumab Injection. | Baseline and 3 months | Growth of the pterygium was defined as an increase in the area of the pterygium as measured from the limbus toward the visual axis. This would be a positive change value indicating progression Regression of the pterygium was defined as a decrease in the area of the pterygium length measured from the limbus toward the visual axis. This would be negative change value indicating regression. |
| Secondary | Number of Patients Having Surgical Removal of Pterygium. | 12 months | The number of patients having surgical removal of pterygium within 12 months. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Area the Pterygium Enlarged or Regressed as Measured From the Limbus Before and After Subconjunctival Bevacizumab Injection. | Baseline and 3 months | All subjects enrolled were analzyed. | area in millimeters squared | MEAN |
| SECONDARY | Number of Patients Having Surgical Removal of Pterygium. | 12 months | All subjects enrolled were analzyed. | Participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Area the Pterygium Enlarged or Regressed as Measured From the Limbus Before and After Subconjunctival Bevacizumab Injection. | Bevacizumab | 5.75 | Standard Deviation 2.91 | area in millimeters squared | |
| Number of Patients Having Surgical Removal of Pterygium. | Bevacizumab | 0 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Bevacizumab | 5 | |
| Overall Study | COMPLETED | Bevacizumab | 5 | |
| Overall Study | NOT COMPLETED | Bevacizumab | 0 |
Source ClinicalTrials.gov
Adverse events3
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Pulling at site of injection of avastin | Eye disorders | Bevacizumab | 2 | 5 | 2 |
| other | Subconjunctival hemorrhage at injection site | Eye disorders | Bevacizumab | 1 | 5 | 1 |
| other | Ocular Irritation | Eye disorders | Bevacizumab | 1 | 5 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Bevacizumab | ||
| Total, other adverse events | Bevacizumab | 4 | 5 |
| Total, serious adverse events | Bevacizumab | 0 | 5 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00592176
GET https://conductscience.org/api/trials/v1/NCT00592176/registered